Efficacy of Selpercatinib in RET -Altered Thyroid Cancers
Lori J. Wirth, Eric Jeffrey Sherman, Bruce G. Robinson et al. · New England Journal of Medicine · 2020
BACKGROUND: -altered thyroid cancers, the efficacy and safety of selective RET inhibition are unknown. METHODS: fusion-positive thyroid cancer, in a phase 1-2 trial of selpercatinib. The primary end point was an objective response (a complete or partial response), as determined by an independent review committee. Secondary end points included the duration of response, progression-free survival, and safety. RESULTS: fusion-positive thyroid cancer, the percentage who had a response was 79% (95% CI, 54 to 94), and 1-year progression-free survival was 64% (95% CI, 37 to 82). The most common adverse events of grade 3 or higher were hypertension (in 21% of the patients), increased alanine aminotransferase level (in 11%), increased aspartate aminotransferase level (in 9%), hyponatremia (in 8%), and diarrhea (in 6%). Of all 531 patients treated, 12 (2%) discontinued selpercatinib owing to drug-related adverse events. CONCLUSIONS: In this phase 1-2 trial, selpercatinib showed durable efficacy with mainly low-grade toxic effects in patients with medullary thyroid cancer with and without previous vandetanib or cabozantinib treatment. (Funded by Loxo Oncology and others; LIBRETTO-001 ClinicalTrials.gov number, NCT03157128.).
Cited by 790 works. doi:10.1056/nejmoa2005651 Open-access PDF
Authors
- Lori J. Wirth
- Eric Jeffrey Sherman
- Bruce G. Robinson
- Benjamin Solomon
- Hyunseok Kang
- Jochen H. Lorch
- Francis Paul Worden
- Marcia S. Brose
- Jyoti D. Patel
- Sophie Leboulleux
- Yann Godbert
- Fabrice Barlési
- Taofeek Kunle Owonikoko
- Daniel S.W. Tan
- Oliver Pascal Gautschi
- Jared Weiss
- Christelle de la Fouchardière
- Mark E. Burkard
- Janessa J. Laskin
References
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
- Integrated Genomic Characterization of Papillary Thyroid Carcinoma
- Lenvatinib versus Placebo in Radioiodine-Refractory Thyroid Cancer
- Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial
- Vandetanib in Patients With Locally Advanced or Metastatic Medullary Thyroid Cancer: A Randomized, Double-Blind Phase III Trial
- Distinct pattern of ret oncogene rearrangements in morphological variants of radiation-induced and sporadic thyroid papillary carcinomas in children.
- Cabozantinib in Progressive Medullary Thyroid Cancer
- Genomic and transcriptomic hallmarks of poorly differentiated and anaplastic thyroid cancers
- Selective RET kinase inhibition for patients with RET-altered cancers
- Highly Prevalent Genetic Alterations in Receptor Tyrosine Kinases and Phosphatidylinositol 3-Kinase/Akt and Mitogen-Activated Protein Kinase Pathways in Anaplastic and Follicular Thyroid Cancers